ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
9 announcements with these filters
Goldline Pharmaceutical Ltd held its 22nd Annual General Meeting on August 29, 2026, where directors and key management presented financial performance and future business outlook.
Promoter Swapan Khandelwal increased his stake in Goldline Pharmaceutical Limited by 0.81% through an open market acquisition of 78,000 shares.
Goldline Pharmaceutical Ltd announced the closure of its Register of Members and Share Transfer Books from August 23 to August 29, 2026, for its AGM.
Goldline Pharmaceutical Limited submitted its Annual Report for the financial year 2025-26, including the notice for the upcoming AGM on August 29, 2026.
Goldline Pharmaceutical Limited has issued a notice for its 22nd Annual General Meeting, scheduled for August 29, 2026. The meeting will address financial statements, dividends, and director re-appointments.
Executive Director Mr. Prashant Shrikrishna Karkare acquired 27,000 equity shares of Goldline Pharmaceutical via an open market purchase. This is a non-promoter insider transaction.
Goldline Pharmaceutical appointed M/s. Avinash Gandhewar & Associates as Secretarial Auditor for FY 2025-26. The appointment was approved during the board meeting held on July 14, 2026.
Goldline Pharmaceutical Ltd reported revenue from operations of ₹17.3 Cr and net profit of ₹2.8 Cr for H2 FY26.
Goldline Pharmaceutical scheduled a board meeting on June 09, 2026, to approve audited financial results. This routine regulatory notice provides advance visibility on upcoming corporate performance disclosures.